A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New York Glaucoma Research Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients older than 18 years of either sex.
2. Patients with open-angle glaucoma with prior glaucoma filtering surgery.
3. IOP above the target range or visual field progression.
4. Have given written informed consent, prior to any investigational procedures.
5. Ability to attend for the 6-month duration of treatment.
You may not be if
1. Closed angle glaucoma (primary or secondary).
2. Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
3. Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or lubricating drops for dry eye (which may be used throughout the study).
4. Any abnormality preventing reliable applanation tonometry of the treated eye.
5. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
6. Participation in any investigational study within the past 30 days.
7. Inability to perform reliable visual field testing.
8. Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary.
9. Self-reported poor compliance to treatment.
10. Reluctance to return for scheduled follow-up visits.
11. Patients not able to understand the nature of the study.
Clareo Health | A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt
